Question-and-Answer Session
Operator
(Operator instructions) We will take our first question from Scott Henry with Roth Capital.
Scott Henry – Roth Capital
Thank you. Good afternoon. Congratulations again, Carl, for finding another $10 million for shareholders that we were not expecting with the Merck deal, certainly give you a lot of credit for that. Just couple questions. First, on the accounting for the Merck deal will that be a one-time benefit in Q3 or will that be amortized over multiple quarters?
Tammy Cameron
Scott, this is Tammy. That will be a one-time recognition when we receive payments we should even recognize that. Again subject to our auditors review.
Scott Henry – Roth Capital
Okay, and then just a question on the Covidien, the pain programs, I guess it wasn’t really clear to me whether you viewed what’s going on with the FDA and Metformin to be a positive or negative. I just wanted to see -- I imagine they are positive or else you might well help the programs. Just wanted to get a little more clarity if you view that as a threat or an opportunity.
Carl Pelzel
Yes, Scott. As you know that we have not been talking about the details related to that program. And the reason we are talking about it now is because there is this conversation with the FDA in the public domain and we felt obliged then to inform shareholders within the context of what risk that may relate to the program. However we and Covidien are very committed to the program and feel very good about bringing these products that we're working on forward into this current environment. Mike, did you wan to?
Mike Sweeney
We view this overall as a positive. The FDA's principal concerns are that people hydrate the opioid and don't tight (inaudible) willingly hydrate. Its Metformin or they take another tyronol product when they are taking these combinations. Our combination to be twice daily combinations with relatively low doses of APA [ph], which will all being well immediately many of the FDA's concerns around APA absolutely and quite positive (inaudible).
Scott Henry – Roth Capital
Okay. Thank you. And then just a couple more pipeline question. I know in the release you target top line results from all three products and I guess early Q4. Because this is such an important event I would just want to press you. Do you said that as a target that you think you can beat or are you confirming that the results will impact happen in Q4? I'm just trying to gauge whether there is any possibility that, that could slide forward into Q3.
- To read the full transcript on Seeking Alpha, click here »
